A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamic (PD) activity of the dual PI3K/mTor inhibitor GDC-0980 administered QW

被引：1
|
作者：
Wagner, A. J. [1 ]
Jayson, G. C. [2 ]
Gomez-Roca, C. [3 ]
Zee, Y. K. [2 ]
Morgan, J. A. [1 ]
Yan, Y. [4 ]
Ware, J. [4 ]
Mazina, K. E. [4 ]
Lauchle, J. [4 ]
Soria, J. C. [3 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Christie NHS Fdn Trust, Manchester, Lancs, England
[3] Inst Cancerol Gustave Roussy, Villejuif, France
[4] Genentech Inc, GRED, San Francisco, CA 94080 USA
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 07期
关键词：
D O I：
10.1016/S1359-6349(10)72096-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：123 / 124
页数：2
相关论文
共 50 条
  • [41] Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma
    Powles, Thomas
    Lackner, Mark R.
    Oudard, Stephane
    Escudier, Bernard
    Ralph, Christy
    Brown, Janet E.
    Hawkins, Robert E.
    Castellano, Daniel
    Rini, Brian I.
    Staehler, Michael D.
    Ravaud, Alain
    Lin, Wei
    O'Keeffe, Bridget
    Wang, Yulei
    Lu, Shan
    Spoerke, Jill M.
    Huw, Ling-Yuh
    Byrtek, Michelle
    Zhu, Rui
    Ware, Joseph A.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (14) : 1660 - U204
  • [42] Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors
    Papadopoulos, Kyriakos P.
    Tabernero, Josep
    Markman, Ben
    Patnaik, Amita
    Tolcher, Anthony W.
    Baselga, Jose
    Shi, Weiliang
    Egile, Coumaran
    Ruiz-Soto, Rodrigo
    Laird, A. Douglas
    Miles, Dale
    LoRusso, Patricia M.
    CLINICAL CANCER RESEARCH, 2014, 20 (09) : 2445 - 2456
  • [43] Retrospective Assessment of Translational Pharmacokinetic-Pharmacodynamic Modeling Performance: A Case Study with Apitolisib, a Dual PI3K/mTOR Inhibitor
    Moein, Anita
    Jin, Jin Y.
    Wright, Matthew R.
    Alicke, Bruno
    Wong, Harvey
    DRUGS IN R&D, 2024, 24 (02) : 155 - 167
  • [44] Changes in plasma components β-oxidation as a pharmacodynamic (PD) biomarker of PI3K inhibition by GDC-0941, a potent, pan-inhibitor of Class I phosphatidyl-inositol-3-kinase (PI3K)
    Ang, Joo Ern
    Pandher, Rupinder
    Asad, Yasmin
    Henley, Alan
    Valenti, Melanie
    Box, Gary
    Brandon, Alexis de Haven
    Eccles, Suzan
    Workman, Paul
    de Bono, Johann S.
    Raynaud, Florence I.
    CANCER RESEARCH, 2013, 73 (08)
  • [45] The combination of GDC-0980, a PI3K/mTOR kinase inhibitor and BAY-86-9766, a MEK inhibitor is able to induce cell growth inhibition of HER2 positive Trastuzumab resistant gastric cancer cell lines
    Savastano, B.
    Laterza, M. M.
    Capasso, A.
    Belli, V.
    Ventriglia, J.
    Petrillo, A.
    Tirino, G.
    Pompella, L.
    Morgillo, F.
    Martinelli, E.
    Orditura, M.
    Ciardiello, F.
    De Vita, F.
    ANNALS OF ONCOLOGY, 2016, 27
  • [46] A preclinical study of a PI3K/mTOR dual inhibitor in the treatment of esophageal adenocarcinoma.
    Omstead, Ashten N.
    Zaidi, Ali Hussainy
    Kosovec, Juliann E.
    Matsui, Daisuke
    Raj, Moses S.
    Biederman, Robert W. W.
    Finley, Gene Grant
    Kelly, Ronan Joseph
    Jobe, Blair A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [47] Preclinical activity of dual PI3K/mTOR inhibitor SPR965 in multiple myeloma
    Larsen, Jeremy T.
    Ramakrishnan, Vijay
    Haug, Jessica
    Kimlinger, Teresa
    Sen, Somdutta
    Mahajan, Dinesh
    Dugar, Sundeep
    Rajkumar, S. Vincent
    Kumar, Shaji K.
    CANCER RESEARCH, 2015, 75
  • [48] A Phase I Dose Expansion Cohort Study of the Safety, Pharmacokinetics and Pharmacodynamics of SAR245409 (S09), An Orally Administered PI3K/mTOR Inhibitor, in Patients with Lymphoma
    Papadopoulos, Kyriakos P.
    Abrisqueta, Pau
    Chambers, Glenda
    Rasco, Drew
    Patnaik, Amita
    Tabernero, Josep
    Rajangam, Kanya
    Rockich, Kevin
    Egile, Coumaran
    Kelly, Adrianne
    Xu, Yi
    Lager, Joanne
    Vose, Julie M.
    BLOOD, 2011, 118 (21) : 699 - 699
  • [49] Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma
    Chen, Ming-Huang
    Chiang, Kun-Chun
    Cheng, Chi-Tung
    Huang, Shih-Chiang
    Chen, Yeng-Yang
    Chen, Tsung-Wen
    Yeh, Ta-Sen
    Jan, Yi-Yin
    Wang, Hsi-Ming
    Weng, Jiang-Jie
    Chang, Peter Mu-Hsin
    Liu, Chun-Yu
    Li, Chung-Pin
    Chao, Yee
    Chen, Ming-Han
    Huang, Chi-Ying F.
    Yeh, Chun-Nan
    ONCOTARGET, 2014, 5 (09) : 2372 - 2389
  • [50] THE DUAL PI3K/mTOR-PATHWAY INHIBITOR GDC-0084 ACHIEVES ANTITUMOR ACTIVITY IN BREAST CANCER BRAIN METASTASES IN VITRO AND IN VIVO
    Ippen, Franziska
    Alvarez-Breckenridge, Christopher
    Kuter, Benjamin
    Fink, Alexandria
    Bihun, Ivanna
    Penson, Tristan
    Ning, Jianfang
    Wakimoto, Hiroaki
    Brastianos, Priscilla
    NEURO-ONCOLOGY, 2018, 20 : 49 - 49
12345